Literature DB >> 17024180

Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2.

Megumi Funakoshi-Tago1, Stephane Pelletier, Tadashi Matsuda, Evan Parganas, James N Ihle.   

Abstract

The tyrosine kinase, Janus kinase-2 (Jak2), plays a pivotal role in signal transduction through a variety of cytokine receptors, including the receptor for erythropoietin (Epo). Although the physiological relevance of Jak2 has been definitively established, less is known about its regulation. In studies assessing the roles of sites of tyrosine phosphorylation, we identified Y(119) in the FERM (band 4.1, Ezrin, radixin and moesin) domain as a phosphorylation site. In these studies, we demonstrate that the phosphorylation of Y(119) in response to Epo downregulates Jak2 kinase activity. Using a phosphorylation mimic mutation (Y(119)E), downregulation is shown to involve dissociation of Jak2 from the receptor complex. Conversely, a Y(119)F mutant is more stably associated with the receptor complex. Thus, in cytokine responses, ligand binding induces activation of receptor associated Jak2, autophosphorylation of Y(119) in the FERM domain and the subsequent dissociation of the activated Jak2 from the receptor and degradation. This regulation occurs with the receptors for Epo, thrombopoietin and growth hormone but not with the receptor for interferon-gamma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17024180      PMCID: PMC1618111          DOI: 10.1038/sj.emboj.7601365

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  43 in total

1.  Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain.

Authors:  Pipsa Saharinen; Mauno Vihinen; Olli Silvennoinen
Journal:  Mol Biol Cell       Date:  2003-04       Impact factor: 4.138

2.  The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.

Authors:  David P Steensma; Gordon W Dewald; Terra L Lasho; Heather L Powell; Rebecca F McClure; Ross L Levine; D Gary Gilliland; Ayalew Tefferi
Journal:  Blood       Date:  2005-04-28       Impact factor: 22.113

3.  Disruption of the SH2-B gene causes age-dependent insulin resistance and glucose intolerance.

Authors:  Chaojun Duan; Hongyan Yang; Morris F White; Liangyou Rui
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

4.  Identification of the two major epidermal growth factor-induced tyrosine phosphorylation sites in the microvillar core protein ezrin.

Authors:  J Krieg; T Hunter
Journal:  J Biol Chem       Date:  1992-09-25       Impact factor: 5.157

5.  Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity.

Authors:  Lawrence S Argetsinger; Jean-Louis K Kouadio; Hanno Steen; Allan Stensballe; Ole N Jensen; Christin Carter-Su
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

6.  Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling.

Authors:  Edward P Feener; Felicia Rosario; Sarah L Dunn; Zlatina Stancheva; Martin G Myers
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

7.  JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin.

Authors:  B A Witthuhn; F W Quelle; O Silvennoinen; T Yi; B Tang; O Miura; J N Ihle
Journal:  Cell       Date:  1993-07-30       Impact factor: 41.582

8.  Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation of JAK2 by SH2-B beta.

Authors:  Jason H Kurzer; Lawrence S Argetsinger; Yong-Jie Zhou; Jean-Louis K Kouadio; John J O'Shea; Christin Carter-Su
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

9.  Janus kinase 2 determinants for growth hormone receptor association, surface assembly, and signaling.

Authors:  Kai He; Xiangdong Wang; Jing Jiang; Ran Guan; Kenneth E Bernstein; Peter P Sayeski; Stuart J Frank
Journal:  Mol Endocrinol       Date:  2003-08-14

10.  Activation of a Drosophila Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects.

Authors:  D A Harrison; R Binari; T S Nahreini; M Gilman; N Perrimon
Journal:  EMBO J       Date:  1995-06-15       Impact factor: 11.598

View more
  27 in total

1.  Phosphorylation of Y372 is critical for Jak2 tyrosine kinase activation.

Authors:  Jacqueline Sayyah; Kavitha Gnanasambandan; Sushama Kamarajugadda; Shigeharu Tsuda; Jennifer Caldwell-Busby; Peter P Sayeski
Journal:  Cell Signal       Date:  2011-06-29       Impact factor: 4.315

Review 2.  Megakaryopoiesis.

Authors:  Amy E Geddis
Journal:  Semin Hematol       Date:  2010-07       Impact factor: 3.851

3.  Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.

Authors:  Shashidhar S Jatiani; Stacey J Baker; Lewis R Silverman; E Premkumar Reddy
Journal:  Genes Cancer       Date:  2010-10

Review 4.  A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.

Authors:  K Gnanasambandan; P P Sayeski
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

5.  A mouse model reveals that Mfsd2a is critical for unfolded protein response upon exposure to tunicamycin.

Authors:  Hiroshi Moritake; Megumi Obara; Yusuke Saito; Ayako Kashimada; Masatoshi Takagi; Megumi Funakoshi-Tago; Tomofusa Fukuyama; Mikio Yoshioka; Akira Inoue; Hiroyuki Komatsu; Hideki Nishitoh; Hiroaki Kataoka; Hiroyuki Nunoi
Journal:  Hum Cell       Date:  2016-11-24       Impact factor: 4.174

Review 6.  Janus kinases in immune cell signaling.

Authors:  Kamran Ghoreschi; Arian Laurence; John J O'Shea
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

7.  Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity.

Authors:  Megumi Funakoshi-Tago; Stéphane Pelletier; Hiroshi Moritake; Evan Parganas; James N Ihle
Journal:  Mol Cell Biol       Date:  2007-12-26       Impact factor: 4.272

Review 8.  The molecular regulation of Janus kinase (JAK) activation.

Authors:  Jeffrey J Babon; Isabelle S Lucet; James M Murphy; Nicos A Nicola; Leila N Varghese
Journal:  Biochem J       Date:  2014-08-15       Impact factor: 3.857

9.  The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.

Authors:  Gerlinde Wernig; Jeffrey R Gonneville; Brian J Crowley; Margret S Rodrigues; Mamatha M Reddy; Heidi E Hudon; Christoph Walz; Andreas Reiter; Klaus Podar; Yohan Royer; Stefan N Constantinescu; Michael H Tomasson; James D Griffin; D Gary Gilliland; Martin Sattler
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

10.  Mechanism of attenuation of leptin signaling under chronic ligand stimulation.

Authors:  Holger Knobelspies; Julia Zeidler; Paul Hekerman; Simone Bamberg-Lemper; Walter Becker
Journal:  BMC Biochem       Date:  2010-01-08       Impact factor: 4.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.